À¯·´ÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå ¿¹Ãø(-2030³â) : Áö¿ªº° ºÐ¼® - Á¦Ç°, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚº°
Europe Deep Brain Simulation Market Forecast to 2030 - Regional Analysis - by Product, Application, and End User
»óǰÄÚµå : 1402482
¸®¼­Ä¡»ç : The Insight Partners
¹ßÇàÀÏ : 2023³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 95 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,450 £Ü 4,937,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù.
US $ 4,450 £Ü 6,368,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,450 £Ü 7,800,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

À¯·´ÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀåÀº 2022³â 1¾ï 6,914¸¸ ´Þ·¯¿¡¼­ 2030³â¿¡´Â 3¾ï 1,988¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. 2022-2030³âÀÇ CAGRÀº 8.3%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ÃßÁ¤µÇ°í ÀÖ½À´Ï´Ù.

Àúħ½À¼ö¼úÀÇ ¼ö¿ä Áõ°¡°¡ À¯·´ÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀåÀ» ÃËÁø

³ú½ÉºÎÀڱؿä¹ýÀº µð½ºÅä´Ï¾Æ, ÆÄŲ½¼º´, º»Å¼º ÁøÀü µî ¿îµ¿Àå¾Ö¸¦ Ä¡·áÇÏ´Â µ¥ »ç¿ëµÇ´Â Àúħ½ÀÀû Ç¥Àû ¼ö¼úÀÔ´Ï´Ù. Àúħ½À ¼ö¼ú(MIS)Àº ±âÁ¸ ¼ö¼ú ¹æ¹ý¿¡ ºñÇØ ¸î °¡Áö ÀåÁ¡ÀÌ Àִµ¥, MIS´Â ½Åü¿¡ ´ëÇÑ ¿Ü»óÀ» ÃÖ¼ÒÈ­Çϰí, ¼ö¼ú ÈÄ ÅëÁõÀ» ÁÙÀ̸ç, ȸº¹ ¼Óµµ¸¦ ³ôÀ̰í, Ä¡·á °á°ú¸¦ Çâ»ó½Ãŵ´Ï´Ù. ·Îº¿ ¼ö¼úÀº ÃÖ¼Ò Ä§½À ¼ö¼úÀÇ ÃֽŠÁøÈ­·Î, ±âÁ¸ º¹°­°æ ¼ö¼ú¿¡ »ç¿ëµÇ´ø °Í°ú µ¿ÀÏÇÑ ÀÛÀº Àý°³Ã¢À» »ç¿ëÇÏ´Â Á¤¹Ð Àåºñ¸¦ ¿Ü°úÀǻ翡°Ô Á¦°øÇϸç, MIS´Â °³º¹ ¼ö¼ú¿¡ ºñÇØ ÃâÇ÷·®ÀÌ Àû°í, ÁøÅëÁ¦ »ç¿ë·®ÀÌ ÀûÀ¸¸ç, ¼ö¼ú ÈÄ ÀÔ¿ø ±â°£ÀÌ Âª½À´Ï´Ù. ¶ÇÇÑ ÃÖ¼Òħ½À¼ö¼úÀº ±âÁ¸ ¼ö¼ú¹ýº¸´Ù ³ôÀº Á¤È®µµ¸¦ º¸ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ MISÀÇ ÀåÁ¡Àº ÀÔ¿ø ȯÀÚ¸¦ ´Ã¸®°í, ³ôÀº ¼ö¼ú ÀÌȯÀ²°ú »ç¸Á·ü¿¡ Á÷¸éÇÑ °í·É ȯÀÚ°¡ ¼ö¼úÀ» ¹Þµµ·Ï À¯µµÇϰí ÀÖ½À´Ï´Ù. ÀÌó·³ ÃÖ¼Òħ½ÀÀû ¼ö¼úÀÇ ÀåÁ¡À¸·Î ÀÎÇÑ ¼ö¿ä Áõ°¡´Â À¯·´ ³ú½ÉºÎÀڱؼú(DBS) ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

À¯·´ÀÇ ³ú½ÉºÎÀÚ±ØÄ¡·á ½ÃÀå °³¿ä

ÀÇ·á ºÐ¾ß¿¡¼­ ½Å°æ¿Ü°ú¼ö¼úÀº ÷´Ü Àåºñ¿Í ÷´Ü ÀÚ°ÝÀ» °®Ãá ÀÇ·á Àü¹®°¡¸¦ ÇÊ¿ä·Î ÇÕ´Ï´Ù. µ¶ÀÏÀÇ ½Å°æ¿Ü°ú ÀÇ»çµéÀº ÷´Ü ÀÚ°ÝÀ» °®Ãá Àü¹®°¡À̸ç ÃֽŠÇÁ·ÎÅäÄݰú ¼ö¼ú ÀýÂ÷¸¦ µû¸£°í ÀÖ½À´Ï´Ù. µ¶ÀÏ ½Å°æÇÐ ¼¾ÅÍ¿¡´Â ±¹Á¦ ǰÁú ±âÁØÀ» ÃæÁ·ÇÏ´Â ÃֽŠÁø´Ü Àåºñ¿Í ÃÖ¼Ò Ä§½À ¼ö¼ú Àåºñ°¡ ¼³Ä¡µÇ¾î ÀÖ½À´Ï´Ù."Deep brain stimulation in Parkinson's"´Â Charite-Universitatsmedizin Berlin¿¡¼­ ¹ßÇ¥µÇ¾ú½À´Ï´Ù, ÆÄŲ½¼º´Àº ¾ËÃ÷ÇÏÀ̸Ӻ´¿¡ ÀÌ¾î µÎ ¹øÂ°·Î ¸¹Àº ½Å°æ ÅðÇ༺ ÁúȯÀÔ´Ï´Ù. µ¶ÀÏ¿¡¼­´Â 2022³â 12¿ù ±âÁØ ¾à 40¸¸ ¸íÀÌ ¾Î°í ÀÖÀ¸¸ç, Àα¸ °í·ÉÈ­·Î ÀÎÇØ ±× ¼ö°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀþÀº ÃþÀ» Æ÷ÇÔÇØ ½Å°æ ÅðÇ༺ ÁúȯÀ» ¾Î°í ÀÖ´Â »ç¶÷ÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, µ¶ÀÏ¿¡¼­´Â 200¸¸ ¸í ÀÌ»óÀÌ Ä¡¸Å¿Í ÆÄŲ½¼º´À» ¾Î°í ÀÖ½À´Ï´Ù. µ¶ÀÏ ¾ËÃ÷ÇÏÀ̸Ӻ´ ȯÀÚÇùȸ¿¡ µû¸£¸é 2020³â¿¡´Â 9,450¸íÀÌ ¾ËÃ÷ÇÏÀ̸Ӻ´À¸·Î »ç¸ÁÇØ °¡Àå ¸¹Àº »ç¸ÁÀÚ¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¾ËÃ÷ÇÏÀÌ¸Ó Áø´ÜÀ¸·Î ÀÎÇÑ ÀÔ¿ø ¹× »ç¸Á Áõ°¡´Â µ¶ÀÏÀÇ °í·ÉÈ­¿¡ Å©°Ô ÀÇÁ¸Çϰí ÀÖÀ¸¸ç, 65¼¼ ÀÌ»ó Àα¸´Â 2020³â µ¿¾È 33% Áõ°¡ÇÏ¿© 1,830¸¸ ¸í¿¡ ´ÞÇß½À´Ï´Ù. µû¶ó¼­ °í·ÉÈ­´Â ½Å°æ Àå¾Ö Áõ°¡¸¦ °¡Á®¿À°í ÀÌ´Â ÇâÈÄ ¼ö³â°£ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

À¯·´ÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå ¸ÅÃâ°ú 2030³â±îÁöÀÇ ¿¹Ãø(±Ý¾×)

À¯·´ÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå ¼¼ºÐÈ­

À¯·´ÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀåÀº Á¦Ç°, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚ, ±¹°¡·Î ±¸ºÐµË´Ï´Ù.

Á¦Ç°º°·Î´Â À¯·´ÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀåÀº ½Ì±Û ä³Î ³ú½ÉºÎ ÀÚ±ØÄ¡·á±â, µà¾ó ä³Î ³ú½ÉºÎ ÀÚ±ØÄ¡·á±â, ¼ÒÇÁÆ®¿þ¾î¿Í ¾×¼¼¼­¸®·Î ±¸ºÐµË´Ï´Ù. 2022³â¿¡´Â µà¾ó ä³Î ½ÉºÎ³ú Àڱر⠺ι®ÀÌ À¯·´ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå¿¡¼­ ÃÖ´ë Á¡À¯À²À» ±â·ÏÇß½À´Ï´Ù.

¿ëµµº°·Î´Â À¯·´ÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀåÀº ÆÄŲ½¼º´, ÁøÀü, ±ÙÀ°±äÀåÀÌ»ó, °£Áú, ¾ËÃ÷ÇÏÀ̸Ӻ´, ±âŸ·Î ±¸ºÐµË´Ï´Ù. 2022³â, ÆÄŲ½¼º´ ºÎ¹®Àº À¯·´ÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå¿¡¼­ ÃÖ´ë Á¡À¯À²À» ±â·ÏÇß½À´Ï´Ù.

ÃÖÁ¾»ç¿ëÀÚº°·Î º¸¸é À¯·´ÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀåÀº º´¿ø, ½Å°æ°úŬ¸®´Ð, ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ, ±âŸ·Î ±¸ºÐµË´Ï´Ù. 2022³â¿¡´Â º´¿ø ºÎ¹®ÀÌ À¯·´³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå¿¡¼­ ÃÖ´ë Á¡À¯À²À» ±â·ÏÇß½À´Ï´Ù.

±¹°¡º°·Î´Â À¯·´ÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀåÀº µ¶ÀÏ, ¿µ±¹, ÇÁ¶û½º, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ, ±âŸ À¯·´À¸·Î ±¸ºÐµË´Ï´Ù. 2022³â¿¡´Â µ¶ÀÏ ºÎ¹®ÀÌ À¯·´ÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå¿¡¼­ ÃÖ´ë Á¡À¯À²À» ±â·ÏÇß½À´Ï´Ù.

Abbott Laboratories, Aleva Neurotherapeutics SA, Boston Scientific Corp»ç, Medtronic Plc, Newronika SpA´Â À¯·´ÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå¿¡¼­ »ç¾÷À» ¿î¿µÇϰí ÀÖ´Â ´ë±â¾÷ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå À¯·´ÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå ±¸µµ

Á¦5Àå À¯·´ÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå : ÁÖ¿ä »ê¾÷ ¿ªÇÐ

Á¦6Àå ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå : À¯·´ ½ÃÀå ºÐ¼®

Á¦7Àå À¯·´ÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå : Á¦Ç°º° ¸ÅÃâ°ú 2030³â±îÁöÀÇ ¿¹Ãø

Á¦8Àå À¯·´ÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå : ¿ëµµº° ¸ÅÃâ°ú 2030³â±îÁöÀÇ ¿¹Ãø

Á¦9Àå À¯·´ÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº° ¸ÅÃâ°ú 2030³â±îÁöÀÇ ¿¹Ãø

Á¦10Àå À¯·´ÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå : ±¹°¡º° ºÐ¼®

Á¦11Àå COVID-19 ÀüÈÄÀÇ ¿µÇâ

Á¦12Àå À¯·´ÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå ¾÷°è »óȲ

Á¦13Àå À¯·´ÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå : ÁÖ¿ä ±â¾÷ °³¿ä

Á¦14Àå ºÎ·Ï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Europe deep brain simulation market is expected to grow from US$ 169.14 million in 2022 to US$ 319.88 million by 2030. It is estimated to grow at a CAGR of 8.3% from 2022 to 2030.

Increasing Demand for Minimally Invasive Surgery Drive Europe Deep Brain Simulation Market

Deep brain stimulation is a minimally invasive targeted surgery used to treat movement disorders in dystonia, Parkinson's disease, and essential tremor. Minimally invasive surgeries (MIS) offer several advantages over traditional surgical techniques. MIS minimizes trauma to the body, reduces postoperative pain, increases recovery speed, and improves outcomes. Robotic procedures represent the latest evolution in minimally invasive procedures, providing surgeons with precision equipment that uses the same small incisions used in traditional laparoscopy. MIS leads to less blood loss, less analgesic use, and shorter postoperative hospital stay than open surgery. In addition, minimally invasive surgery indicates a higher accuracy rate than traditional surgical methods. Also, these procedures require tiny incisions large enough to insert thin tubes and cameras. These benefits of MIS are increasing inpatients and have encouraged older patients who face high operative morbidity and mortality to seek surgery. Thus, the rising demand for minimally invasive surgeries due to their advantages bolsters the Europe deep brain stimulation (DBS) market growth.

Europe Deep Brain Simulation Market Overview

In the medical field, neurosurgery requires advanced equipment and highly qualified medical professionals. German neurosurgeons are highly qualified specialists; they follow the latest protocols and surgical procedures. Neurology centers in Germany have the most modern diagnostic and minimally invasive surgical devices that meet international quality standards. According to a study published at Charite-Universitatsmedizin Berlin entitled "Deep brain stimulation in Parkinson's: A new algorithm to adjust stimulation settings has been developed," Parkinson's disease is the second most common neurodegenerative disease after Alzheimer's. Approximately 400,000 people were affected with the disease in Germany in December 2022, and the numbers are increasing due to demographic aging. More and more people, including younger people, suffer from neurodegenerative diseases; in Germany, more than 2 million people have dementia or Parkinson's. According to the German Association for Alzheimer's Patients, in 2020, 9,450 people died from Alzheimer's, recording the highest figure. The increase in hospitalizations and deaths with Alzheimer's diagnosis is highly dependent on the aging population in Germany. People aged 65 and above increased by ~33% between and reached 18.3 million in 2020. Therefore, the aging population results in growing neurological disorders, which is expected to boost the market growth in the coming years.

Europe Deep Brain Simulation Market Revenue and Forecast to 2030 (US$ Million)

Europe Deep Brain Simulation Market Segmentation

The Europe deep brain simulation market is segmented into product, application, end user, and country.

Based on product, the Europe deep brain simulation market is segmented into single channel deep brain stimulator, dual channel deep brain stimulator, and software and accessories. In 2022, the dual channel deep brain stimulator segment registered the largest share in the Europe deep brain simulation market.

Based on application, the Europe deep brain simulation market is segmented into Parkinson's disease, tremor, dystonia, epilepsy, Alzheimer's disease, and others. In 2022, the Parkinson's disease segment registered the largest share in the Europe deep brain simulation market.

Based on end user, the Europe deep brain simulation market is segmented into hospitals, neurology clinics, ambulatory surgical centers, and others. In 2022, the hospitals segment registered the largest share in the Europe deep brain simulation market.

Based on country, the Europe deep brain simulation market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. In 2022, Germany segment registered the largest share in the Europe deep brain simulation market.

Abbott Laboratories, Aleva Neurotherapeutics SA, Boston Scientific Corp, Medtronic Plc, and Newronika SpA are some of the leading companies operating in the Europe deep brain simulation market.

Reasons to Buy:

Table Of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Europe Deep Brain Simulation Market Landscape

5. Europe Deep Brain Simulation Market - Key Industry Dynamics

6. Deep Brain Simulation Market - Europe Market Analysis

7. Europe Deep Brain Simulation Market - Revenue and Forecast to 2030 - by Product

8. Europe Deep Brain Simulation Market - Revenue and Forecast to 2030 - by Application

9. Europe Deep Brain Simulation Market - Revenue and Forecast to 2030 - by End User

10. Europe Deep Brain Simulation Market - Country Analysis

11. Pre & Post Covid-19 Impact

12. Europe Deep Brain Simulation Market Industry Landscape

13. Europe Deep Brain Simulation Market, Key Company Profiles

14. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â